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Background: Sensitive and specific detection of nodal status, sites of metastases and low-volume recurrent disease
could greatly improve management of patients with advanced prostate cancer. Prostate-specific membrane antigen
(PSMA) is a well-established marker for prostate carcinoma with increased levels of expression in high-grade,
hormone-refractory and metastatic disease. The monoclonal antibody (mAb) J591 is directed against an extracellular
epitope of PSMA and has been shown to efficiently target disseminated disease including metastases in lymph
nodes and bone. Its use as a diagnostic imaging agent however is limited due to its slow pharmacokinetics. In this
study a diabody derived from mAb J591 was developed as a single photon emission computed tomography
(SPECT) tracer with improved pharmacokinetics for the detection of PSMA expression in prostate cancer.
Methods: A diabody in VH-VL orientation and with a C-terminal cysteine was expressed in HEK293T cells and purified
by a combination of metal ion affinity and size exclusion chromatography. Specificity and affinity were determined in
cell binding studies. For SPECT imaging, the diabody was site-specifically labelled with [99mTc(CO)3]
+ via the C-terminal
His tag and evaluated in a subcutaneous DU145/DU145-PSMA prostate carcinoma xenograft model.
Results: J591C diabody binds to PSMA-expressing cells with low nanomolar affinity (3.3 ± 0.2 nM). SPECT studies
allowed imaging of tumour xenografts with high contrast from 4 h post injection (p.i.). Ex vivo biodistribution studies
showed peak tumour uptake of the tracer of 12.1% ± 1.7% injected dose (ID)/g at 8 h p.i. with a tumour to blood ratio
of 8.0. Uptake in PSMA-negative tumours was significantly lower with 6.3% ± 0.5% at 8 h p.i. (p < 0.001).
Conclusion: The presented diabody has favourable properties required to warrant its further development for
antibody-based imaging of PSMA expression in prostate cancer, including PSMA-specific uptake, favourable
pharmacokinetics compared to the parental antibody and efficient site-specific radiolabelling with 99mTc.
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Molecular imagingBackground
Prostate cancer (PCa) has a good prognosis when localised
to the prostate gland or when disease has not spread
beyond the regional lymph nodes. However, the 5-year
survival rate drops from 99% to approximately 27%
in patients with evidence of distant metastases [1].
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of sites of metastases and low-volume recurrent disease.
Prostate-specific membrane antigen (PSMA; also
known as glutamate carboxypeptidase II (GPCII)) is a
well-established marker for prostate carcinoma. Elevated
expression of PSMA is found in virtually all prostate
cancers with the highest levels found in high-grade,
hormone-refractory and metastatic disease [2-6]. Expression
of PSMA is also found in the neo-vasculature of solid
tumours [7]. Expression in non-malignant tissue is
found in the prostate epithelium and, to a limited extent,
in brush border cells of the duodenum, kidney proximalis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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crypts and in the brain [3,7,8]. Imaging studies with
PSMA-specific small molecules in man have further
shown accumulation in lacrimal and salivary glands [9,10].
This very restricted expression pattern makes PSMA an
excellent target for detection and targeted therapy of
prostate cancer. Several studies have demonstrated a
correlation between increased PSMA expression and
higher Gleason score. Although not validated as a
predictive marker, it has been suggested that PSMA
expression levels in the primary tumour can predict
disease outcome [11,12].
Several antibodies that recognise extracellular epitopes of
PSMA have been developed [13,14]. The monoclonal anti-
body (mAb) J591 was the first of these described, and the
targeting properties of a de-immunised version have been
characterised in several combined radioimmunotherapy
and imaging clinical studies [15-19]. Despite the excellent
targeting properties reported in these studies, imaging
had to be performed several days after injection of the
tracer in order to obtain images of sufficient contrast as a
result of the long circulation time of the full-length
antibody conjugate.
Antibodies can be engineered into smaller fragments
that largely retain the original antigen binding properties
but with more rapid pharmacokinetics, potentially enabling
tracer injection and imaging on the same day. Diabodies
with their intermediate size of approximately 55 kDa are
likely to represent a good balance between circulation
time/systemic clearance, target accumulation and tissue
penetration; good contrast images can be obtained within
1 to 8 h in preclinical studies [20-22]. They consist only of
the variable domains of an antibody connected by a short
(typically five to eight amino acids) linker, which promotes
the formation of a small, bivalent and homo-dimeric
protein. Introduction of an additional cysteine at or near
the C-terminus can result in the formation of an
inter-chain disulfide bond that further stabilises the
otherwise non-covalent dimer (Additional file 1). Diabodies
against various targets have been engineered and
radiolabelled for preclinical imaging studies, mainly
using positron emission tomography (PET) [23-26].
99mTc is an attractive choice for labelling intermediate-
sized recombinant proteins such as diabodies for single
photon emission computed tomography (SPECT), for
several reasons. First, the tricarbonyl chemistry allows
direct chelation of 99mTc by genetically encoded tags,
such as the (His)6-tag, which simplifies the labelling
process [27]. Second, its half-life of 6 h matches well
with the average serum half-life of diabodies. Third, it
provides excellent image quality at low radiation doses
compared to isotopes with a longer half-life such as 111In
and 89Zr that are needed for imaging with whole
antibodies.Here we describe the development and preclinical
evaluation of a diabody derived from the anti-PSMA
antibody J591, site-specifically labelled with 99mTc, for
SPECT imaging of PSMA expression in prostate cancer.
Methods
Antibody construction, expression and purification
A single-chain fragment variable (scFv) of J591 in VH-VL
orientation was PCR-amplified from the SFG P28z
vector [28], converting it into a diabody by shortening
the linker to GGGGS using overlapping primers. The
diabody was cloned into pSEC-tag2 (Invitrogen, Carlsbad,
CA, USA)-based mammalian expression vector pMS-C
with N-terminal Ig-kappa leader and a C-terminal
(His)6-tag followed by a cysteine (J591Cdia). A diabody
without C-terminal cysteine was generated to evaluate the
effect of the additional cysteine. HEK293T cells were trans-
fected with the expression vector using Lipofectamine
2000 (Life Technologies, Paisley, UK), and transfected cells
were selected with 100 μg/ml Zeocin (Life Technologies)
before expanding to triple flasks for protein production.
The diabody was purified from HEK293T culture
supernatant by Ni-NTA chromatography (5 mL Ni-NTA
Superflow Cartridge, Qiagen, Manchester, UK) followed by
a gel filtration step (Superdex 75 HR 10/30, GE-Healthcare,
Little Chalfont, UK) using an AKTA FPLC system
(GE-Healthcare). Purified protein (in phosphate-buffered
saline (PBS; pH 7.0) for subsequent maleimide conjugation
or PBS/500 mM NaCl, pH 7.4, for 99mTc labelling) was
concentrated to >1 mg/mL and stored in aliquots at −80°C.
Purity was assessed by Coomassie staining after sodium
dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) and analytical size exclusion high-pressure
liquid chromatography (HPLC) (BioSep SEC-s2000,
Phenomenex, Cheshire, UK). Protein concentration
was determined by UV absorption at 280 nm using
the molar extinction coefficient of the diabody
(E280nm, 51,130 M
−1 cm−1; MWmonomer, 27.18 kDa;
determined with ProtParam [29]).
Generation of PSMA-expressing DU145 cells
A synthetic DNA fragment that encodes for PSMA was
synthesised by GenScript (Piscataway, NJ, USA). To
allow cloning into SFG, the fragment consisted of bases
6137 to 6344 of the SFG P28z retroviral vector (includes
a 5′ AgeI site [28]), followed by a codon-optimised
cDNA that encodes for full-length human PSMA and
flanked by a 3′ XhoI site. This fragment was cloned
as an AgeI-XhoI fragment into SFG, replacing bases
6137 to 6344 of the vector. Retrovirus was packaged
using PG13 cells (European Collection of Cell Cultures,
Porton Down, UK). Transduction of DU145 cells
(Cancer Research UK Organization) with SFG PSMA was
performed using conditioned medium derived from PG13
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anti-human PSMA antibody (clone K0142-3, MBL
International, Woburn, MA, USA) followed by collection of
PSMA-expressing cells using sheep anti-mouse Ig-coated
paramagnetic beads (Life Technologies, Paisley, UK).
Cell culture
Human prostate carcinoma cells DU145, DU145-PSMA
and LNCaP (LCG Standards, Bury, UK: CRL-1740) were
cultured in RPMI 1640 supplemented with 10% FBS,
2 mM L-glutamine and penicillin/streptomycin (cell
culture reagents and consumables were purchased
from PAA, Somerset, UK). For induction of tumours,
sub-confluent cells were washed with PBS, harvested by
brief trypsinisation and re-suspended, after an additional
washing step, in RPMI 1640 medium with 3.5 × 106 cells
in 50 to 80 μl.
Fluorophore conjugation
Fluorophores were conjugated to the diabody via the
C-terminal cysteines. The protein in PBS/2 mM
EDTA (pH 7.0) was incubated for 30 min at 37°C with a
10-fold molar excess of TCEP (Bond-Braker, Pierce
Biotechnology, Rockford, IL, USA) before addition of a
20-fold molar excess Alexa488-C5-maleimide (Life
Technologies) for 2 h at room temperature (RT).
Unconjugated fluorophore was removed by size exclusion
chromatography using a Superdex 75 column, and the
conjugated protein was concentrated using MWCO
membrane spin filters (Vivaspin 2, MWCO 5000, Sartorius,
Darmstadt, Germany).
Flow cytometry
Saturation binding studies were carried out to analyse
the in vitro binding properties of the diabody. PSMA+
or PSMA− cells (4 × 105) were incubated with serial
dilutions of fluorescein- or Alexa488-labelled diabody
in 250 μl PBS for 30 min on ice. Mean fluorescence
values were determined by flow cytometry (FACSCalibur
with Cellquest software, BD Biosciences, Oxford, UK),
and the signal obtained with the highest concentration of
J591Cdia-Alexa488 on DU145-PSMA cells was set as
100%. Data were analysed using a one-site total binding
model (GraphPad Prism version 5.00 for Windows,
GraphPad Software, San Diego, CA, USA).
Confocal microscopy
Receptor-mediated internalisation of J591Cdia was
analysed by confocal microscopy. DU145 or DU145-PSMA
cells were seeded in chamber slides (Lab-Tek, Fisher
Scientific, Loughborough, UK) and incubated when
confluent with 4 μg/ml of J591Cdia-Alexa488 for
30 min at 4°C or 37°C. Nuclear counterstaining was
achieved using 4′,6-diamidino-2-phenylindole (DAPI;ProLong Gold, Life Technologies, Paisley, UK). Pictures
were taken with a TCS SP5 II confocal microscope (Leica,
Milton Keynes, UK).
99mTc radiolabelling
For imaging and biodistribution and cell binding studies,
the diabody was labelled with 99mTc-tricarbonyl ([99mTc
(CO)3]
+) via the C-terminal (His)6-tag. The IsoLink kit
(Covidien, Petten, The Netherlands) was used to convert
2,200 to 2,500 MBq of 99mTc pertechnetate in 400 to
500 μl saline to [99mTc(CO)3]
+. After heating to 97°C for
30 min, the kit was neutralised with 1 M HCl and
conversion to [99mTc(CO)3]
+ was verified by thin-layer
chromatography (TLC; glass-backed silica gel 60, Merck,
Darmstadt, Germany; mobile phase: 1% HCl in methanol).
The diabody was incubated at 37°C with 5.5 MBq/μg
for 1 h and passed through a G25 Minitrap column
(GE-Healthcare, Little Chalfont, UK) to remove residual
unbound 99mTc and potential colloids. Labelling and
final radiochemical purity were monitored by TLC in
60 mM citrate buffer, pH 5.5 (iTLCSA, Rf protein = 0, Rf
[99mTc(CO)3]
+ = 1) and analytical HPLC SEC (BioSep
SEC-s2000, Phenomenex). Protein concentration after gel
filtration was determined by UV absorption after decay
using an aliquot stored at −80°C.
Cell binding studies
Binding properties of the radiolabelled diabody were
analysed in homologous competition studies. Cells
(5 × 104 DU145 or DU145-PSMA cells/well) were seeded
in 96-well plates, grown overnight and incubated the next
day with serial dilutions of J591Cdia (1,850 to 0.03 nM)
and a constant concentration of 99mTc-labelled diabody
(1 nM) at 4°C for 45 min. Cells were washed with
3 × 100 μl cold PBS and lysed with 2 × 50 μl 0.5 M
NaOH. Cell-associated activity was measured by gamma
counting (1282 Compugamma Universal Gamma
Counter, LKB Wallac, PerkinElmer, Cambridge, UK).
Data were analysed with GraphPad Prism and fitted using




The diabody was labelled with 99mTc as described above,
mixed 1/1 with fresh human serum and incubated at 37°C.
Samples were taken at 0, 15, 30, 60, 120 and 240 min and
analysed by thin-layer chromatography using iTLCSA chro-
matography paper (Agilent Technologies, Wokingham, UK)
and 100 mM citrate buffer (pH 5.2) as mobile phase. To
discriminate serum-bound and antibody-bound activity,
samples taken at the same time points were frozen in
liquid nitrogen, separated by SDS-PAGE (12% NuPAGE,
Invitrogen, Paisley, UK) and analysed by autoradiography
(Cyclone Plus, PerkinElmer, Waltham, USA).
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Animal studies were carried out in accordance with UK
Research Councils' and Medical Research Charities'
guidelines on Responsibility in the Use of Animals in
Bioscience Research, under UK Home Office Project and
Personal licences. Male SCID beige mice aged 6 to 10 weeks
(Charles River, Margate, UK) were used for all experiments.
Cells (3 to 4 × 106 DU145 or DU145-PSMA cells) were
injected subcutaneously on the left flank in 50 μl RPMI
1640 medium, and animals were used for imaging or
biodistribution studies after 4 to 5 weeks, when tumours
reached approximately 5 mm in diameter. The DU145/
DU145-PSMA model was used instead of the commonly
used LNCaP/PC3 combination of tumours to take
advantage of the more reproducible growth of the
xenografts. The use of the same cell line with and
without target receptor expression should further allow a
more accurate evaluation of specific versus unspecific
uptake in the tumour tissue.
Biodistribution studies
Labelled diabody (J591Cdia-[99mTc(CO)3]
+, 10 to 13 μg)
was injected via the tail vein, and mice were sacrificed
after 8 h (four mice/group). Organs were dissected,
briefly washed in PBS, blotted dry and weighed. Activity
in whole organs and tumours was measured by gamma
counting and is expressed as percent injected dose
(ID)/gram. The total injected dose was determined by
weighing the syringes before and after injection and
referring to serial dilutions of the labelled antibody,
prepared from a separate syringe and measured along
with the dissected organs.
In vivo SPECT imaging
Single photon emission tomography was performed with
a small-animal SPECT/CT scanner (Mediso, Budapest,
Hungary) under isofluorane anaesthesia and respiration
monitoring. Mice (three to four mice/group) were
injected via the tail vein with 25 to 35 MBq of labelled
diabody (10 to 13 μg, 0.22 to 0.24 nmol in 50 to 80 μl
PBS), and helical SPECT/CT images were acquired at 0,
20 and 40 min, and again at 4 and 8 h post injection
(with 15, 30 and 45 min of acquisition time). CT images
were acquired after each SPECT scan.
Image analysis
SPECT images were reconstructed with HiSPECT™ soft-
ware (Bioscan, Washington, DC, USA). CT images were
reconstructed using the SPECT/CT scanner-embedded
software package. Maximum intensity projection (MIP)
images were generated and scaled individually. To quantify
tumour and muscle uptake, tissues were identified in the
CT images and regions of interest covering the entire
tumour were drawn in all slices acquired. Relative uptakevalues were used to generate time-activity curves for
individual tumours.
Immunofluorescence staining of tumour sections
For ex vivo validation of PSMA expression in individual
tumours, tissue was harvested at the end of an experiment
and frozen in liquid nitrogen. Cryo-sections (10 μm) were
prepared and stained with the AlexaFluor-488-labelled
version of the J591C diabody. Briefly, air-dried sections
were fixed with 4% formalin, washed with PBS and
incubated with 1.4 μg/ml labelled diabody in PBS/1%
BSA for 45 min at RT. Sections were washed with
PBS, slides were mounted with mounting media containing
DAPI to counterstain nuclei (ProLong Gold, Invitrogen)
and images were taken with a TCS SP5 II confocal
microscope (Leica, Wetzlar, Germany).
Statistical analysis
Unless otherwise stated, values are shown as mean ±
standard deviation (SD). Data were analysed for statistical
significance using GraphPad Prism version 5.00 for
Windows. Unless otherwise stated, an unpaired, two-tailed
t test was used. Statistical significance was assigned for
p values <0.05.
Results
Diabody expression, purification and in vitro
characterisation
The diabody was produced in HEK293T cells with yields
of purified protein (purity >95%) of 4 to 6 mg/L culture
supernatant. The diabody was present as a dimer of
54 kDa with the C-terminal cysteines forming a disulfide
bond in 80% to 90% of the protein, as shown by
SDS-PAGE analysis of reduced and unreduced samples
(Figure 1a). Dimer formation does not depend on the
C-terminal cysteine. When expressed without the
cysteine, the diabody (J591dia), as the version with
cysteine, elutes as a dimer in size exclusion HPLC. In
both cases, no monomeric diabody was detected during
purification or subsequent size exclusion HPLC analyses.
Binding properties of the J591Cdia were analysed by flow
cytometry and confocal microscopy. For this purpose,
the protein was labelled with Alexa488-maleimide or
fluorescein maleimide via its C-terminal cysteine. In
saturation binding assays, the diabody showed specific
binding to PSMA+ cells with a Kd of 3.3 ± 0.2 nM
(mean of four independent experiments).
The diabody is internalised rapidly upon incubation
with DU145-PSMA cells as determined by confocal
microscopy. After 20 min at 37°C, all labelled diabody
was detected in intracellular vesicles while at 4°C
mostly membrane staining was observed. No binding
was detected on DU145 cells (Figure 1d).
Figure 1 In vitro characterisation of J591C diabody. (a) SDS-PAGE of purified J591C diabody. The reduced sample runs as a single band corresponding
to the size of the monomer (27 kDa). In the non-reduced sample, the majority of protein is present as a covalent dimer through formation of a disulfide
bond by the C-terminal cysteines. (b) Analytical size exclusion HPLC. The UV chromatogram shows elution as a single dimeric species. (c) Saturation
binding assay on DU145-PSMA and LNCaP cells with J591Cdia-AlexaFluor-488, labelled via the C-terminal cysteines and analysed by flow cytometry.
DU145-PSMA cells show higher PSMA expression levels than LNCaP. (d) Binding and internalisation studies with the AlexaFluor-488-labelled diabody in
DU145-PSMA and DU145 cells at 4°C and 37°C (20 min of incubation). (e) Competitive binding assay with 1 nM [99mTc(CO)3]
+-labelled diabody vs.
unlabelled diabody as cold competitor on DU145-PSMA and DU145 cells (data representative of four independent experiments).
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site-specific chelation of [99mTc(CO)3]
+ by the C-terminal
(His)6-tag. The labelling method consistently yielded >85%
labelling after 1 h and >95% after 2 h of incubation at 37°C
(Additional file 2). After 1 h of incubation, the labelled
diabody was separated from unbound activity by a gel filtra-
tion step resulting in a final radiochemical purity of >99%
(Additional file 2) and a corresponding specific activity of
4.2 MBq/μg (231 MBq/nmol diabody).
Stability of the radiolabel upon incubation in human
serum was analysed by iTLCSA and SDS-PAGE. No loss
of radiolabel was observed over a period of 4 h at 37°C
(Additional file 2). Similarly, no activity was released
upon incubation in PBS (data not shown), and no
significant trans-chelation of [99mTc(CO)3]
+ to serum
proteins was observed (Additional file 2).
Competitive binding studies with 99mTc-labelled vs.
unlabelled J591Cdia confirmed specific binding to
PSMA+ cells with a Kd of 5.0 nM ± 0.5 (n = 4; Figure 1e).
DU145/DU145-PSMA tumour model
LNCaP cells were used as a reference for the amount of
PSMA expressed by the transfected DU145 cells. Bmax
values obtained from saturation binding studies were used
to compare expression levels, showing an approximately2.4 times higher number of receptors on DU145-PSMA
cells (Figure 1c). The tumour take rate (tumours of >3 ×
3 mm at 4 weeks post injection (p.i.)) was >80% for
both DU145 and DU145-PSMA cells (n = 46). PSMA
expression in the PCa xenografts was determined
ex vivo by immunofluorescence staining of tumour
sections (Figure 2). Cryo-sections were stained using the
diabody conjugated to AlexaFluor-488. In agreement with
flow cytometry data using the DU145 and DU145-PSMA
cell lines (not shown), a heterogeneous expression pattern
was observed in all DU145-PSMA tumour sections while
staining was absent from DU145 tumours.
Biodistribution and SPECT imaging
Targeting properties of the [99mTc(CO)3]
+-labelled
J591Cdia were assessed by serial SPECT/CT imaging of
tumour-bearing mice from 20 min to 8 h p.i. and by ex vivo
biodistribution studies. The serial images shown in
Figure 3a demonstrate that J591Cdia was initially observed
in the blood pool (at 0 to 60 min), followed by a progres-
sive increase in uptake in the liver, kidneys and bladder,
owing to urinary excretion (4 and 8 h time points). No
excretion via the hepato-biliary route was observed.
The diabody accumulated specifically in PSMA+ tumours
with a clear delineation of the tumour observed from 4 h
Figure 2 Ex vivo verification of PSMA expression in DU145-PSMA and DU145 tumours. Immunofluorescence staining of tumour cryo-sections
was performed using J591Cdia-AlexaFluor-488 (green). Nuclei are counterstained with DAPI (blue). Three representative tumour sections are shown.
All analysed DU145-PSMA sections showed strong, heterogeneous staining for PSMA. No staining was observed in DU145 tumour sections.
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images (three to four mice/group) show the highest
accumulation of the tracer at 8 h p.i. and slightly lower
uptake at 4 h p.i. (Figure 3d). The ratio of PSMA-specific vs.
unspecific accumulation (DU145-PSMA/DU145 tumour)
was 1.8 (4 h) and 2.1 (8 h), respectively. Injection of
a 20-fold excess of unlabelled diabody reduced
DU145-PSMA tumour uptake to the same level observed
in the PSMA-negative DU145 tumours.
Results from the ex vivo biodistribution study are shown
in Figure 4 (and Table 1). The diabody accumulated in the
tumour with 12.1% ± 1.7% ID/g at 8 h p.i. High uptake
was also observed in the kidneys (29.2% ± 1.7% ID/g), liver
(13% ± 0.9% ID/g) and spleen (10.1% ± 1.4% ID/g). The
tumour to blood and tumour to muscle ratios at 8 h p.i.
were 8.0 and 16.8, respectively. The tumour uptake in the
DU145 control group was significantly lower, with
6.3% ± 0.5% at 8 h p.i. (p < 0.001) and a PSMA+ to
PSMA− ratio of 1.9. The tumour to blood and tumour to
muscle ratios were 3.3 and 4.8, respectively. Unexpectedly,
higher activity was observed in several organs in the
DU145 group compared to the DU145-PSMA group
(44% injected dose (ID) vs. 67% ID in all organs at 8 h p.i.).
The average tumour weight was 66 ± 14.6 mg for
DU145-PSMA and 80 ± 24.5 mg for DU145 (no significant
difference in weight, p > 0.5).
Discussion
A J591-derived diabody was developed, labelled with
99mTc and characterised as a SPECT tracer for imagingof PSMA expression in prostate cancer. The use of a
diabody combines the specificity and targeting proper-
ties of the parental antibody with more favourable
pharmacokinetics for imaging purposes.
The J591C diabody (J591Cdia) was produced as a
stable dimer with good yields obtained by batch expression
in HEK293T cells. The use of C-terminal cysteines to
promote formation of covalent dimers and for the purpose
of site-specific modification has been described previously.
In accordance with published data, we observed the
formation of an inter-chain disulfide bond in up to
90% of the purified protein [30,31]. Both versions of
the J591C diabody, either fluorescently labelled via
the C-terminal cysteines or radiolabelled with intact
inter-chain disulfide bond, bound to PSMA-expressing
cells with low nanomolar affinity. The chelation of
[99mTc(CO)3]
+ by genetically encoded histidine tags
offers a simple yet site-specific and stable means to label
proteins with 99mTc [27,32], obviating the additional step
of conjugating a chelator to the protein. For the J591C
diabody, this labelling method proved robust, allowing for
reproducible labelling to high specific activity.
Antibody fragment-based radiotracers should allow
earlier image acquisition as compared to their full-
length antibody counterparts, without compromising
the sensitivity and specificity of detection. In clinical
studies with 111In- or 177Lu-labelled versions of the
parental full-length antibody hJ591, a serum half-life
(T1/2 β) of 44 ± 15 h was reported and clear images
were obtained as late as 4 to 7 days post injection
Figure 3 MIP images of SPECT/CT scans with 99mTc-J591Cdia in mice bearing subcutaneous prostate carcinoma tumours. Mice with
established DU145-PSMA or control DU145 tumours received 10 to 13 μg (between 25 and 35 MBq/injection) of 99mTc-J591Cdia by tail vein
injection. (a) Serial images at 5 min, 60 min, 4 h and 8 h post injection of a mouse with DU145-PSMA tumour. (b) Mouse with PSMA-negative
DU145 tumour at 8 h p.i. (c) Mouse with DU145-PSMA tumour; binding of 99mTc-J591Cdia blocked with a 20 times excess of unlabelled diabody
(cold competition, at 8 h p.i.). (d) Tumour uptake values in the DU145-PSMA (n = 3), DU145 (n = 3) and cold competition (comp, n = 4) groups
over time as determined from SPECT/CT images (shown as mean ± SD). Arrows indicate the position of the tumour in each image. Images are
scaled individually.
Figure 4 Ex vivo biodistribution of 99mTc-J591Cdia in mice with subcutaneous DU145 or DU145-PSMA tumours p.i. (a) DU145-PSMA
tumour. (b) DU145 tumour. As for the imaging studies, mice (n = 4) with established tumours received 10 to 13 μg (between 25 and 35 MBq/injection)
of 99mTc-J591Cdia by tail vein injection. Tracer uptake in selected organs at 8 h p.i., as measured by gamma counting, is expressed as mean percent
injected dose/gram.
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Table 1 Ex vivo biodistribution of 99mTc-J591Cdia at 8 h
post injection
Organ DU145-PSMA DU145
Tumour 12.1 ± 1.7 6.3 ± 0.5
Blood 1.5 ± 0.2 1.9 ± 0.4
Stomach 1.4 ± 0.3 2.2 ± 0.1
Small intestine 1.4 ± 0.2 2.4 ± 0.2
Large intestine 1.7 ± 0.3 2.7 ± 0.3
Spleen 10.1 ± 2.8 18.0 ± 1.2
Liver 13.0 ± 1.8 20.5 ± 2.5
Kidneys 29.2 ± 3.5 51.4 ± 3.2
Heart 2.7 ± 0.3 5.8 ± 0.5
Lungs 5.5 ± 1.2 6.0 ± 0.6
Muscle 0.7 ± 0.2 1.3 ± 0.3
Bone 2.0 ± 0.4 4.0 ± 0.4
Reproductive organs 1.8 ± 0.7 3.2 ± 0.4
Salivary glands 2.4 ± 0.7 4.5 ± 0.4
Skin 1.4 ± 0.4 3.1 ± 0.5
Tumour to blood ratio 8 3.3
Tumour to muscle ratio 16.8 4.8
Ratio of DU145-PSMA to DU145
tumour uptake
1.9 -
Ex vivo biodistribution of 99mTc-J591Cdia in mice with subcutaneous DU145 or
DU145-PSMA tumours at 8 h post injection (n = 4). Values are expressed as
mean percent injected dose per gram of tissue (% ID/g) ± SD.
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(DFO)-huJ591 conjugate showed a plateau in uptake
in LNCaP tumours from about 48 h p.i. [34]. By
contrast, the T1/2 β of diabody molecules in mice has
been reported as between 1 and 7 h [21,23,35,36],
and 4 to 12 h post injection has been suggested as
the optimal time point for diabody imaging [20]. In
keeping with this, the J591C diabody shows a plateau
in accumulation in the tumour from about 4 h p.i.
and good tumour to blood and tumour to muscle ratios at
8 h p.i. (8 and 16.8). An excess of cold diabody could block
tumour uptake efficiently. The elevated uptake in DU145
tumours (lacking PSMA) is presumably a result of the
enhanced permeation and retention (EPR) effect, which is
commonly found in well-perfused tumours and with
molecules of this size.
The liver uptake observed in our study is moderate
(13% ± 0.9% ID/g) and comparable to that found for
the full-length 89Zr-(DFO)-huJ591 [34]. Whether this
partial hepatic clearance interferes with the detection
of potential metastases in the liver will have to be
investigated. Since the choice of the radiolabel can
influence uptake and retention in target and non-target
tissues [37], alternative labels may be compared in
follow-up studies.We observed a higher activity in several organs in the
DU145 compared to the DU145-PSMA group. The reason
for this is unclear; a possible explanation may be a slower
initial renal filtration of the tracer and a resulting higher
uptake in susceptible organs in the different batch of mice.
The extent of kidney uptake and retention suggests
binding of J591Cdia to PSMA expressed in the renal
proximal tubules. This has been observed similarly in
preclinical studies with small-molecule inhibitors targeting
PSMA [38,39]. Renal excretion can potentially interfere
with the detection of small lesions or recurrent disease in
the prostate bed, although this has not been reported to
be a prominent issue in clinical studies with the small
PSMA inhibitors [9,10].
Site-specific PEGylation has been shown to gradually
reduce renal filtration of a diabody with increasing PEG
size and increased tumour uptake as a result of the longer
circulation time [22]. This strategy could potentially be
adopted for the J591Cdia, however at the cost of lower
contrast at early time points.
Several urea-based inhibitors of the glutamate
carboxypeptidase activity of PSMA have been described
and developed as diagnostic tracers. Recently, promising
results of phase 1 clinical trials with two 123I-labelled
compounds and a 68Ga-labelled molecule were reported
[9,10]. A 99mTc-labelled version showed excellent bio-
distribution properties preclinically with rapid renal
clearance and tumour to blood and tumour to muscle
ratios of 550 and 157, respectively, at 4 h p.i. [38]. This
compound is currently in a phase II trial (ClinicalTrials.
gov Identifier: NCT01667536).
Comparison of these small-molecule tracers with the re-
sults of two ongoing PCa imaging trials with 89Zr-(DFO)-
huJ591 (ClinicalTrials.gov Identifier: NCT01543659)
and a 89Zr-labelled minibody derivative (ClinicalTrials.
gov Identifier: NCT01923727) in terms of their sensitivity
and specificity may indicate the future potential of
antibody-based imaging of PSMA.
Conclusion
In conclusion, a diabody derived from the well-established
anti-PSMA antibody J591 was engineered and shown
to specifically target PSMA-positive tumours allowing
for SPECT imaging with high contrast from 4 to 8 h
post injection.Additional files
Additional file 1: Schematic of a full-length antibody and a diabody
with C-terminal cysteine.
Additional file 2: Radiolabelling of J591C diabody with [99mTc(CO)3]
+.
Figure showing the labelling of J591Cdia with [99mTc(CO)3]
+ over time as
measured by TLC and analysis of serum stability of 99mTc-J591Cdia as
measured by TLC and SDS-PAGE.
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